{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:28:01Z","timestamp":1786436881172,"version":"build-2736575974"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007683","name":"Nihon University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K08597"],"award-info":[{"award-number":["JP22K08597"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Salivary therapeutic drug monitoring of linezolid has been proposed as a non-invasive alternative to blood sampling for pharmacokinetic assessment. However, the salivary disposition and pharmacokinetics of the two major linezolid metabolites, PNU-142300 and PNU-142586, have not been characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the salivary disposition and serum protein binding of PNU-142300 and PNU-142586 using pharmacokinetic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this exploratory study, six healthy adult volunteers received a single intravenous dose of linezolid. Serial blood and saliva samples were collected for 10\u2005h after dosing. The total and protein-unbound concentrations of linezolid and its two major metabolites, PNU-142300 and PNU-142586, were quantified using validated high-performance liquid chromatography methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Linezolid was consistently quantifiable in saliva, and its salivary concentration\u2013time profile closely followed that of protein-unbound serum exposure. PNU-142300 and PNU-142586 were readily quantifiable in blood but remained below the lower limit of quantification in saliva in all participants at all sampling time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Under the conditions studied, linezolid was quantifiable in saliva, whereas its two major metabolites were not, indicating different salivary disposition profiles for the parent drug and its metabolites. Salivary concentrations were consistent with protein-unbound serum exposure to linezolid under the conditions studied, whereas exposure to PNU-142300 and PNU-142586 could not be assessed using saliva and required blood-based measurements in the present study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag280","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:38:54Z","timestamp":1785843534000},"source":"Crossref","is-referenced-by-count":0,"title":["Differential salivary disposition of linezolid and its two major metabolites (PNU-142300 and PNU-142586) after a single dose in healthy adults"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7967-2947","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsuji","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University , 7-7-1 Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-101X","authenticated-orcid":false,"given":"Hitoshi","family":"Kawasuji","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences , 2630 Sugitani, Toyama, Toyama 930-0194 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1370-4202","authenticated-orcid":false,"given":"Tomona","family":"Yamada","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University , 7-7-1 Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Kurosaki","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University , 7-7-1 Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, School of Pharmacy, Nihon University , 7-7-1, Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makito","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences , 2630 Sugitani, Toyama, Toyama 930-0194 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmacometrics, School of Pharmacy, Nihon University , 7-7-1 Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Laboratory of Medicinal Chemistry, School of Pharmacy, Nihon University , 7-7-1, Narashinodai, Funabashi, Chiba 274-8555 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-8724","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences , 2630 Sugitani, Toyama, Toyama 930-0194 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026081103330527100_dkag280-B1","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2026081103330527100_dkag280-B2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00027-20","article-title":"Accumulation of major linezolid metabolites in patients with renal impairment","volume":"64","author":"Souza","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081103330527100_dkag280-B3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.641872","article-title":"A novel UPLC-MS\/MS assay for the measurement of linezolid and its metabolite PNU-142300 in human serum and its application to patients with renal insufficiency","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026081103330527100_dkag280-B4","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.xphs.2021.02.014","article-title":"Classification tree analysis based on machine learning for predicting linezolid-induced thrombocytopenia","volume":"110","author":"Takahashi","year":"2021","journal-title":"J Pharm Sci"},{"key":"2026081103330527100_dkag280-B5","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081103330527100_dkag280-B6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/jac\/dkad191","article-title":"Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia","volume":"78","author":"Xu","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026081103330527100_dkag280-B7","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70124","article-title":"Evaluating the impact of linezolid metabolites: PNU-142300 and PNU-142586 on the development of linezolid-induced thrombocytopenia in adult patients","volume":"66","author":"Sakurai","year":"2026","journal-title":"J Clin Pharmacol"},{"key":"2026081103330527100_dkag280-B8","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1128\/AAC.00558-13","article-title":"Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis","volume":"57","author":"Bolhuis","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081103330527100_dkag280-B9","doi-asserted-by":"publisher","first-page":"1901903","DOI":"10.1183\/13993003.01903-2019","article-title":"Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin","volume":"55","author":"van den Elsen","year":"2020","journal-title":"Eur Respir J"},{"key":"2026081103330527100_dkag280-B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s13318-023-00836-6","article-title":"Monitoring salivary concentrations of tedizolid and linezolid using rats","volume":"48","author":"Inoue","year":"2023","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2026081103330527100_dkag280-B11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1128\/AAC.46.5.1345-1351.2002","article-title":"Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia","volume":"46","author":"Gentry-Nielsen","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026081103330527100_dkag280-B12","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1111\/bcp.13262","article-title":"Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients","volume":"83","author":"Tsuji","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026081103330527100_dkag280-B13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/bmc.3441","article-title":"A simple high-performance liquid chromatography for the determination of linezolid in human plasma and saliva","volume":"29","author":"Hara","year":"2015","journal-title":"Biomed Chromatogr"},{"key":"2026081103330527100_dkag280-B14","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/jac\/dkaf169","article-title":"High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid","volume":"80","author":"Kawasuji","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026081103330527100_dkag280-B15","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3390\/ph18121821","article-title":"A unified approach to synthesizing four linezolid metabolites that may cause thrombocytopenia","volume":"18","author":"Oikawa","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026081103330527100_dkag280-B16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.15583\/jpchrom.2025.018","article-title":"Simultaneous determination of linezolid, PNU-142300, and PNU-142586 in human serum via Ion-pairing reversed-phase liquid chromatography with UV detection","volume":"47","author":"Kurosaki","year":"2026","journal-title":"Chromatography"},{"key":"2026081103330527100_dkag280-B17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1248\/cpb.40.127","article-title":"Simple method of calculating octanol water partition-coefficient","volume":"40","author":"Moriguchi","year":"1992","journal-title":"Chem Pharm Bull"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag280\/70607351\/dkag280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/9\/dkag280\/70607351\/dkag280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:33:14Z","timestamp":1786433594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag280\/8758716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag280","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,4]]},"article-number":"dkag280"}}